uniQure Presents Clinical Data from Ongoing Phase I/II Study in Hemophilia B Demonstrating 6 Months of Sustained Increases in Factor IX Activity
June 11, 2016 05:45 ET
|
uniQure
--Data from Low-Dose Cohort Presented at the 21st Congress of the European Hematology Association Show Durable and Therapeutically Relevant Factor IX (FIX) Expression--
--Median FIX...
uniQure Announces Results for First Quarter 2016
May 31, 2016 05:00 ET
|
uniQure
AMSTERDAM, the Netherlands, May 31, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced financial results for the first quarter ending March 31, 2016,...
uniQure Announces Oral Presentation of Clinical Data from Ongoing Phase I/II Study of AMT-060 in Hemophilia B at the 21st Congress of the European Hematology Association
May 19, 2016 06:00 ET
|
uniQure
– Presentation to Include Most Recent Clinical Data from the Five Patient, Low-dose Cohort –
– Company to Host Conference Call on Monday, June 13, 2016 at 2:00 pm CET/ 8:00 am...
uniQure to Present at Upcoming Investor Conferences in New York City
May 12, 2016 05:00 ET
|
uniQure
AMSTERDAM, the Netherlands, May 12, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced that its management will be presenting at the below listed...
uniQure Announces the Nomination of Jack Kaye to its Board of Directors and Proposed Corporate Governance Changes
May 09, 2016 16:24 ET
|
uniQure
AMSTERDAM, The Netherlands, May 9, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced the nomination of Jack Kaye to stand for election to uniQure's...
uniQure Announces the Nomination of Jack Kaye to its Board of Directors and Proposed Corporate Governance Changes
May 09, 2016 16:15 ET
|
uniQure
AMSTERDAM, the Netherlands, May 9, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced the nomination of Jack Kaye to stand for election to uniQure's...
uniQure Presents Preclinical Data on AAV Re-Administration, Regulated Gene Expression and Total Brain Transduction at ASGCT
May 09, 2016 05:00 ET
|
uniQure
AMSTERDAM, the Netherlands, May 9, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced the data from several preclinical research programs focused on...
uniQure Appoints Paul Firuta as Chief Commercial Officer
May 03, 2016 05:00 ET
|
uniQure
AMSTERDAM, the Netherlands, May 3, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced the appointment of Paul Firuta as Chief Commercial Officer. Mr....
uniQure To Present Data On Gene Therapy Technology Advances At Annual Meeting Of The American Society Of Gene And Cell Therapy
April 19, 2016 09:23 ET
|
uniQure
AMSTERDAM, The Netherlands, April 19, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced that six abstracts have been accepted for poster...
uniQure To Present Data On Gene Therapy Technology Advances At Annual Meeting Of The American Society Of Gene And Cell Therapy
April 19, 2016 09:16 ET
|
uniQure
AMSTERDAM, The Netherlands, April 19, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced that six abstracts have been accepted for poster...